Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
-
Foundation for Sarcoidosis Research Launches New Clinical Data Registry
-
Foundation for Sarcoidosis Research Expands Insurance and Disability Support for Sarcoidosis Patients
-
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
-
FSR and ATS are pleased to welcome joint new hire John Matthew “Matt” Craig, PhD.
-
Foundation for Sarcoidosis Research Launches See Sarcoidosis Campaign for April's Awareness Month
-
Foundation for Sarcoidosis Research is proud to receive 2025 RareVoice Award for Federal Advocacy and attend Rare Disease Month on Capitol Hill
-
FSR Invests in New Round of Research Awards to Drive Breakthroughs in Diagnosis and Treatment of Sarcoidosis
-
NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Orphai Therapeutics Inc. (“Orphai”), a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for patients with...
-
Foundation for Sarcoidosis Research welcomes clinics to Global Sarcoidosis Clinic Alliance.